Using Antibody-Dependent Cellular Cytotoxicity in the Rx Industry
With over 30 years of experience, Cell Technology has been able to accomplish a lot. Thus, our prestigious clients can vouch for our restless desire to be innovative leaders in our field. With that said, we’re using Antibody-Dependent Cellular Cytotoxicity as a crucial pre-clinical step in the pharmaceutical industry. But, what does that mean exactly?
Diving into Antibody-Dependent Cellular Cytotoxicity (ADCC)
First, ADCC is a machine of a cell-mediated immune defense. This means that it can strategically pick out a cell that has been bound by specific antibodies. For the pharmaceutical world, this is great news. Secondly, this means more research can be done on immune systems. In this way, we’re using ADCC to determine “the activity of the antibody and/or complement against specified target cell lines.” As such, we have an assay platform that we can mold. Therefore, it can select antibody drug candidates.